Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
08/2010
08/17/2010US7777069 Prodrugs of carbamate inhibitors of IMPDH
08/17/2010US7777057 Derivatives of dioxan-2-alkyl carbamates, preparation thereof and application thereof in therapeutics
08/17/2010US7776902 N-[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenylsulfonyl]-4-nitrooxybutanamide, used for the treatment of inflammatory, cardiovascular, gastrointestinal, respiratory and nervous system disorders, as analgesics, antipyretics and antocoagulants or for organ and tissue preservation
08/17/2010US7776898 Opioid receptor active compounds
08/17/2010US7776895 Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
08/17/2010US7776879 anticholinergic agents such as Butylthiophen-2-ylmethylcarbamic acid 1-azabicyclo[2.2.2]oct-3-(R)yl ester, having a high affinity for muscarinic M3 receptors, useful for treating respiratory system, urogenital, gastrointestinal and cardiovascular disorders
08/17/2010US7776854 1,3-benzothiazol-2-yl(2-{[4-(morpholin-4-ylmethyl)benzyl]oxy}pyrimidin-4-yl)-acetonitrile; (or benzimidazole or benzoxazole 2-acetonitrile derivatives); systemic sclerosis, CREST, sine scleroderma, cirrhosis, heart failure; inhibitors of JNK (c-Jun N-terminal Kinases)
08/17/2010US7776850 respiratory tract mucositis; administering an antifungal agent and an antibacterial agent, wherein the treatment does not involve the cessation of use of emollients
08/17/2010US7776820 Methods for decreasing risk of complications of prematurity using IGF-I and its analogs
08/17/2010US7776340 has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (eg Quebec and LY138) and human coronavirus strain OC43
08/17/2010CA2461963C Cyclic amine compounds
08/17/2010CA2461212C Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
08/17/2010CA2385269C Novel thiazolo(4,5-d)pyrimidine compounds
08/17/2010CA2382940C 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
08/12/2010WO2010090612A1 Stable, taste and odor masked pharmaceutical compositions comprising acetylcystein and vitamin c
08/12/2010WO2010090222A1 Hb-egf-bound protein complex
08/12/2010WO2010089391A1 New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
08/12/2010WO2010089107A1 Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors
08/12/2010WO2010039977A3 Heteroaryl antagonists of prostaglandin d2 receptors
08/12/2010US20100204336 Formoterol Tartrate Process and Polymorph
08/12/2010US20100204332 Method for treating a disease or condition responsive to opening of c1c-2 channel
08/12/2010US20100204321 Antitussive and Bronchodilator uses for enaminone ester
08/12/2010US20100204295 Treatment of allergic disease with immunomodulator compounds
08/12/2010US20100204282 Reverse indoles as 5-lipoxygenase-activating protein (FLAP) inhibitors
08/12/2010US20100204256 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
08/12/2010US20100204232 Xinafoate salt of n4-(2,2-difluoro-4h-benz0 [1,4] oxazin-3-one) -6-yl] -5-fluoro-n2- [3-(methylaminocar bonylmethyleneoxy) phenyl] 2,4-pyrimidinediamine
08/12/2010US20100204225 Organic compounds
08/12/2010US20100204223 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof
08/12/2010US20100204222 Pyridopyrimidine derivatives as p13 kinase inhibitors
08/12/2010US20100204213 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
08/12/2010US20100204212 Fused heterocyclic compounds useful as kinase modulators
08/12/2010US20100204211 Medicaments for the treatment or prevention of fibrotic diseases
08/12/2010US20100204210 Method for treating pulmonary diseases using rho kinase inhibitor compounds
08/12/2010US20100204209 CCR2 Receptor Antagonists and Uses Thereof
08/12/2010US20100204205 Tolerability of mirtazapine and a second active agent by using them in combination
08/12/2010US20100204203 Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors
08/12/2010US20100204182 Ectonucleotidase inhibitors
08/12/2010US20100204181 N-halogenated amino acid formulations comprising phosphine or amine oxides
08/12/2010US20100204170 Heterobifunctional pan-selectin inhibitors
08/12/2010US20100204158 Combination of splenopentin and thymopentin and the use thereof in medicine
08/12/2010US20100204157 Use of a peptide as a therapeutic agent
08/12/2010US20100204156 Use of thymopentin as a therapeutic agent
08/12/2010US20100204155 Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents
08/12/2010US20100204154 Use of the peptide rfmwmr as a therapeutic agent
08/12/2010US20100204153 Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection
08/12/2010US20100204152 Use of gluten exorphin c : as a therapeutic agent
08/12/2010US20100204151 Use of a peptide as a therapeutic agent
08/12/2010US20100204150 Use of a peptide as a therapeutic agent
08/12/2010US20100204149 Use of octreotide as a therapeutic agent
08/12/2010US20100204148 (d-leu7 ) -histrelin as a therapeutic agent
08/12/2010US20100204145 Use of a peptide as a therapeutic agent
08/12/2010US20100204144 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents
08/12/2010US20100204143 Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent
08/12/2010US20100204142 Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
08/12/2010US20100204141 Use of bpp-b as a therapeutic agent
08/12/2010US20100204140 Use of a peptide as a therapeutic agent
08/12/2010US20100204139 Use of gonadorelin as a therapeutic agent
08/12/2010US20100204138 Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents
08/12/2010US20100204136 Use of a peptide as a therapeutic agent
08/12/2010US20100204135 Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s)
08/12/2010US20100204134 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-ard-gly-asp-asn-pro-oh as a therapeutic agent
08/12/2010US20100204132 THERAPEUTIC USES OF PEPTIDES YSAYPDSVPMMS and WMNSTGFTKVCGAPPC
08/12/2010US20100204131 Use of a peptide as a therapeutic agent
08/12/2010US20100204129 Use of a peptide as a therapeutic agent
08/12/2010US20100204118 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents
08/12/2010US20100204117 Cgrp as a therapeutic agent
08/12/2010US20100204116 Use of calcitonin as anti-angiogenic agent
08/12/2010US20100204115 Use of acetyl- (ala10, 11)-rantes (1-14) and/or calcitonin as anti-angiogenic agents
08/12/2010US20100204114 Use of a galanin peptide as a therapeutic agent
08/12/2010US20100204113 Use of stresscopin-related peptide as a therapeutic agent
08/12/2010US20100204112 Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents
08/12/2010US20100204111 Astressin and beta- endorphin for use as therapeutic agents
08/12/2010US20100204110 Use of a peptide as a therapeutic agent
08/12/2010US20100204109 Use of c-type natriuretic peptide, alone or in combination with neuropeptide af, as a therapeutic agent
08/12/2010US20100204108 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents
08/12/2010US20100204107 Use of urodilatin as a therapeutic agent
08/12/2010US20100204090 Use of a peptide as a therapeutic agent
08/12/2010US20100204089 Phosphorylated pyrone analogs and methods
08/12/2010US20100203628 Novel modified galectin 9 proteins and use thereof
08/12/2010US20100203172 Sodium nitrite-containing pharmaceutical compositions
08/12/2010US20100203166 Methods of preventing respiratory infections
08/12/2010US20100203069 Antisense Respiratory Syncytial Virus Vaccine and Therapy
08/12/2010US20100203042 Recombinant anti-vla4 antibody molecules
08/12/2010US20100202979 Compositions and methods for treatment of pulmonary diseases and conditions
08/12/2010US20100202977 Modulation of Stat 6 Expression for the Treatment of Airway Hyperresponsiveness
08/12/2010CA2751494A1 Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors
08/11/2010EP2216409A1 Albumin fusion proteins
08/11/2010EP2216327A1 Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
08/11/2010EP2216047A1 Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient
08/11/2010EP2215119A1 Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
08/11/2010EP2215094A1 N-containing heterocyclic compounds
08/11/2010EP2215093A1 Novel piperazino-dihydrothienopyrimidine derivatives
08/11/2010EP2215092A1 Substituted piperidino-dihydrothienopyrimidines
08/11/2010EP2215089A1 [1h- pyrazolo [3, 4-b]pyridine-4-yl]-phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
08/11/2010EP2215087A2 Xinafoate salt of n4- (2,2-difluoro-4h-benzo [1,4] oxazin-3-one) - 6-yl] - 5-fluoro-n2 - [3-(methylaminocarbonylmethyleneoxy) phenyl] 2,4-pyrimidinediamine
08/11/2010EP2214714A1 A new class of therapeutics that enhance small molecule diffusion
08/11/2010EP2214706A1 Use of trkb antibodies for the treatment of respiratory disorders
08/11/2010EP2214686A1 Calcium-rich alkaline powder produced from processed molluse shells
08/11/2010EP2214673A1 Novel phenyl-substituted piperazino-dihydrothienopyrimidines
08/11/2010EP2214658A1 Osmolyte-containing preparation for use in case of dry mucous membranes
1 ... 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 ... 878